Robot-assisted radical cystectomy: patient selection and special considerations

Abstract

Robot-assisted (RA) procedures are increasingly being performed as minimally invasive surgical approaches. Less insensible losses due to a closed abdomen, smaller incisions with less retractor strain, decreased analgesic requirements, and earlier postoperative ambulation are suggested advantages of robot-assisted radical cystectomy (RARC). Patients who undergo open radical cystectomy are also candidates for RARC procedure. However, the steep Trendelenburg position and pneumoperitoneum develop a non-physiological condition. Intra-abdominal adhesions preventing the placement of the ports and patients who cannot tolerate the pneumoperitoneum and/or steep Trendelenburg position are special contraindications of RARC. Besides, body mass index >30 kg/m², presence of extravesical disease, bulky lymphadenopathy, previous vascular surgery, previous distal colorectal surgery, previous pelvic radiation, previous pelvic trauma, and/or preexisting cardiovascular/pulmonary disease that is compromised with positioning are not certainly contraindicated but unwanted conditions in which the RARC may be performed successfully as the surgeons gain experience.

Introduction

Open radical cystectomy (ORC) with extended pelvic lymph node dissection (PLND) is the “gold standard” surgical approach in patients with muscle-invasive bladder cancer, in addition to patients with high-grade, recurrent, non-invasive tumors despite conservative treatments.¹

Robot-assisted (RA) procedures are increasingly being performed as minimally invasive surgical approaches. Robot-assisted radical cystectomy (RARC) has the advantages of decreased blood loss, decreased time to flatus, decreased time to bowel movement, and decreased analgesic use, all of which may allow adjuvant chemotherapy administration at more appropriate time when needed and/or increased quality of life in post-surgery period compared with ORC.^1,2

Many patients with ORC indication are candidates for RARC except some special contraindications such as presence of intra-abdominal adhesions preventing the placement of the ports and patients who cannot tolerate the pneumoperitoneum and/or steep Trendelenburg (ST) position.³

Additionally, body mass index (BMI) >30 kg/m², presence of extravesical disease, bulky lymphadenopathy, previous vascular surgery, previous distal colorectal surgery, previous pelvic radiation, previous pelvic trauma, and/or preexisting cardiovascular/pulmonary disease that is compromised with positioning are not certainly contraindicated but unwanted characteristics. Besides, as the surgeon gains experience, RARC may also be performed successfully in the patients possessing these conditions.

Obesity

Obesity emerges as an important health care problem associated with increased health care costs, higher risk of comorbidity, and premature deaths.⁴ Two large series evaluated obese patients in terms of ORC outcomes. Chang et al reported that obesity leads to higher blood loss and longer operative times.⁵ Lee et al reported that elevated BMI results in increased complication rate, operative time, and estimated blood loss.⁶

Poch et al evaluated the influence of BMI on RARC and intracorporeal ileal conduit diversion.⁷ They found that BMI >30 kg/m² results in significantly increased blood loss compared with normal and overweight patients – mean 500 mL. However, that was less than reported for obese patients in large open series. BMI was not found to be associated with increased length of stay (LOS) or increased severity of complications compared to the open series.⁷ However, the number of complications was similar in all BMI classes in contrast with previous open series.⁷ Moreover, Butt et al found no difference in operative time, blood loss, and complication rates between all BMI subgroups in a 51-patient series that underwent RARC and extracorporeal ileal conduit.⁸

Due to the literature and to our own experience, RARC with extracorporeal or intracorporeal urinary diversion might be performed safely in overweight and obese patients.

Advanced age

Bladder cancer is most commonly seen in elderly patients with a significantly increased incidence by the age of 70 years.⁹

Coward et al reported the operative outcomes and pathologic results of 99 patients who underwent RARC, categorized by age (younger vs > 70-year-old).¹⁰ There was no statistically significant difference between the two groups in terms of estimated blood loss, interval to bowel movement, and interval to discharge.¹⁰ Despite the significantly higher American Society of Anesthesiology (ASA) scores observed in elderly patients compared to the younger patients, they did not find significant difference in complication rates.¹⁰ Richards et al compared ORC and RARC performances at >75-year-old patients.¹¹ Estimated blood loss, median hospital stay, and number of total and major complications were significantly lower in the RARC group.¹¹

Groote et al showed that median operative time, median estimated blood loss, median LOS, reoperation rate, and perioperative complications for low-grade and high-grade tumors in addition to overall complications according to the Clavien–Dindo system were similar between patients <80 years and octogenarians.¹² Octogenarian patients undergoing RARC who have high risk in terms of non-muscle-invasive and muscle-invasive bladder cancer were not found to have increased risk for peri- and postoperative morbidity and mortality rates.¹²

RARC have several challenges due to the additional comorbidities increasing by age in elderly patients. Another concern is that elderly patients might less tolerate complications and comorbidities compared to younger patients who have more physiological capacity. Aging is accompanied by a decrease in the lung tissue elasticity and a decreased response to hypoxemia and/or hypercapnia.¹³ However, despite these physiologic changes, the pneumoperitoneum as well as the ST position in RARC may well be tolerated by elderly.¹¹

Cardiopulmonary performance

Determining the cardiopulmonary performance status of patients is one of the most important pre-assessments before radical cystectomy, especially in the elderly. This evaluation contributes to predict the postoperative adverse outcomes.^14–16 The tools that are mostly used for this purpose are ASA index, Charlson comorbidity index, and Eastern Cooperative Oncology Group performance index.

Cardiopulmonary exercise testing (CPET) is another method with distinct advantage of measuring the physiological oxygen exchange efficiency and cardiorespiratory function (CRF) individually. Variables derived from CPET including anaerobic threshold (AT) and oxygen consumption (VO₂) are predictors of major complications and LOS after ORC and RARC with extracorporeal urinary diversion (eRARC). Patients with a low AT (<11 mL/kg/min) appear to be at high risk of complications and death. The peak VO₂ and ventilatory equivalent for carbon dioxide (VE/VCO₂) are also important as they provide a measure of lung efficiency.¹⁷ This allows clinicians to create a personalized risk profile with which postoperative morbidity and mortality can be predicted.^18–20

Prentis et al evaluated 82 patients undergoing ORC by CPET. They found a significant difference in LOS between the patients who had a major (Clavien score >3) perioperative complication and the patients who did not (16 vs 30 days; P<0.001).¹⁸ Tolchard et al evaluated 105 patients in terms of the relationship between CPET and complications after RC undergoing ORC or eRARC and they found AT was negatively, and VE/VCO₂ positively, correlated with complications and LOS.¹⁹ Lamb et al evaluated 82 patients undergoing RARC with intracorporeal urinary diversion (iRARC). They found no significant difference in AT, peak VO₂, or VE/VCO₂ between patients who had complications and those who did not.²¹ Undergoing iRARC, low cardiorespiratory reserve did not predict the occurrence of major complications and LOS.

The morbidity and mortality associated with RC have been reduced in recent years; therefore, iRARC may present as an additional means of improving patient outcomes.

Preoperative anemia

Preoperative anemia is commonly seen and the incidence increases in patients receiving neoadjuvant chemotherapy. Also hematuria and the chronic process of the disease may lead to anemia, and thus the incidence of anemia is higher in elderly patients than in younger patients. Preoperative anemia may negatively affect the perioperative outcomes.

Tan et al evaluated iRARC performed in 166 patients in a study in which 72 of them were anemic.²² Conversely, the results suggested that preoperative anemia was not associated with median LOS, 30- and 90-day morbidity, and 90-day readmission rates in iRARC-performed patients. Anemia alone was not found to be associated with higher complication rates. Besides, blood transfusion requirement was the most deterministic factor associated with perioperative complications.²²

Oncologic outcomes

In the European Association of Urology Robotic Urology Section (ERUS) Scientific Working Group database, 717 patients were identified at 9 different institutions who underwent iRARC.²³ The median follow-up was 31 months. Recurrence-free survival (RFS) rates at 3, 12, and 24 months were 95.9%, 80.2%, and 74.6%, respectively. Any unusual recurrence pattern after RARC was not identified in this multi-institutional study.²³ Early recurrences at any site were detected in 4.1% of patients at 3 months, 19.8% at 12 months, and 25.4% at 24 months similar with the rates in ORC series. Eighteen percent of RARC patients had positive lymph nodes and 32.6% had pT3/4 disease. Early recurrence rates and recurrence sites were similar with those for ORC series.^24–26

Tan et al evaluated 184 bladder cancer patients who underwent RC.²² Number of ORC cases was 94 and the number of iRARC cases was 90. Median follow-up without recurrence was 33.8 months for ORC and 16.1 months for iRARC. Overall, median follow-up was 22.8 months. Between the two groups, there was no significant difference in cancer-specific survival (80.9% ORC vs 84.4% iRARC), RFS (65.9% ORC vs 75.2% iRARC), and overall survival (OS) (72.5% ORC vs iRARC 79.2%) at 24 months. No significant difference was observed in age, sex, precystectomy grade, precystectomy T stage, and lymph node yield between ORC and iRARC. Most of the cases were urothelial cell carcinoma (UCC) and no significant difference was found in precystectomy pathological T stage. No significant difference was detected between number of lymph nodes resected, local and metastatic RFS, recurrence patterns, and oncological outcomes.²⁷

Collins et al evaluated iRARC-performed 70 patients whose data were collected prospectively and reviewed retrospectively. The unadjusted survival rates at 24 months for recurrence-free, cancer-specific-free, and overall survival were 80.7%, 88.9%, and 88.9%, respectively. They found that the oncologic outcome results were similar with ORC series exhibiting iRARC as a safe and feasible method.²⁸

Concomitant surgery

Alkan et al reported a case of simultaneous robotic nephroureterectomy (RANU), genital tract and nerve-sparing RARC with super-extended pelvic lymph node (LN) dissection, and intracorporeal Studer urinary reconstruction on a female patient with muscle-invasive bladder and a distal ureteral tumor.²⁹ Barros et al evaluated eight patients (seven males, one female) with bladder cancer and of those, seven patients underwent laparoscopy and one patient underwent RARC with RANU (unilateral [n=6], bilateral [n=2]).³⁰ Ou et al simultaneously performed RANU and RARC on eight patients (five females, three males) with UCC and uremia.³¹ Justin et al reported a patient who underwent RA laparoscopic combined nephroureterectomy and radical cystoprostatectomy with extended PLND and extracorporeal ileal conduit urinary diversion.³²

All of the studies concluded that simultaneous RANU and RARC may be safely performed. En bloc removal of kidney, ureter, prostate, and bladder may be done safely by utilizing minimally invasive techniques such as robotic surgery that seems to be technically safe and feasible with excellent oncological outcomes and minimal complications.

Patient positioning (steep Trendelenburg position) and pneumoperitoneum

RARC is performed in 30° ST position. This may adversely affect intracranial pressure (ICP), eye and middle ear pressures during prolonged operative time periods.

Positioning patient in the ST position in combination with pneumoperitoneum leads to cerebral oxygen saturation decrease by a clinically insignificant value of <5% over a time period exceeding 4 h.³³ ICP increases in the ST position and additional pneumoperitoneum can further elevate ICP. Increased ICP results in reduced venous drainage of the brain leading to cerebral edema. Increased ICP and cerebral edema may result in cerebral hypoperfusion and ischemia.³⁴ Pandey et al reported two patients who underwent a prolonged ST positioning of about 7–10 h for RARC. The patients developed cerebral edema with consequent neurologic damage.³⁵

Severe neurological complications are generally rare. Minor clinical symptoms such as nausea and headache related with increased ICP are likely to be seen more frequently after laparoscopy.^36–38

The increase in ICP may lead to partial or complete vision loss, retinal detachment, and ischemic optic neuropathy.^39–41 Intraocular pressure (IOP) increases significantly in the ST position.⁴² This increase results in hemodynamic changes in eye. In RARC, ocular complication risk is low despite the requirement to stay in the ST position for a long time. Ozcan et al evaluated 53 patients (robot assisted laparoscopic radical prostatectomy: 43; iRARC: 10) intraoperatively in terms of the effect of the ST on IOP, resistive index of the central retinal artery, and venous impedance index of the central retinal vein prosectively.⁴³ There was no difference between the IOP values of the right and left eyes in both groups. The highest IOP values were identified in patients under anesthesia during intraperitoneal CO₂ insufflation or at the end of the operation. Despite staying in the ST for a long time, ophthalmologic examination was normal.⁴³

Routine preoperative ophthalmologic examination is not warranted and patients should be questioned before the operation with regard to any history of ophthalmic disease such as glaucoma. Ocular hypertension and/or glaucoma may be a risk factor in RARC. The IOP values may also affect glaucoma patients who possess ocular blood flow abnormalities. Elevated IOP (up to 45 mmHg) and short-term changes in ocular perfusion pressure do not affect normal eyes due to autoregulatory mechanism on blood flow to the optic nerve head.⁴⁴ It is proposed that patients with ocular preexisting diseases such as glaucoma should be referred to an ophthalmologist preoperatively.

Bozkirli et al evaluated ASA physical status I–III in 35 patients, aged 18–80, undergoing robot-assisted radical prostatectomy (RARP) in the ST position prospectively to evaluate middle ear pressure (MEP) changes related to the ST position and CO₂ pneumoperitoneum.⁴⁵ They found that the ST position with pneumoperitoneum in RARC significantly increases MEP and this increase may continue through the first hour postoperation. The prolonged response may be related with the CO₂ diffusion to the middle ear or the time and degree of the ST position.⁴⁵

Increase in MEP may lead to undesirable clinical outcomes. Postoperative intractable nausea, vomiting, rupture of membranes, and even facial nerve damages may be seen due to significant and long-term increases in MEP.^46–48 During the preanesthetic evaluation of patients, detailed anamnesis of ear diseases should be questioned and consultation by an ear, nose, and throat specialist should be done before RARP and RARC surgeries.

There is no sufficient evidence about the safety of the ST position while performing RARC in the presence of cerebral aneurysm, arteriovenous malformation, and meningioma. As a matter of fact, many patients do not know that they have such a special condition. Therefore, further studies are needed on this issue.

Unexpected conditions

We previously reported two cases of RARC with bilateral extended PLND and intracorporeal Studer pouch formation in patients with duplicated right ureters.⁴⁹ Ureteric duplication is a rarely seen malformation of the urinary tract more commonly seen in females. Duplicated ureters might be underdiagnosed on CT and we do not think that this rare entity is a contraindication to use the robot in this complicated procedure. Ureteric duplication can be successfully managed at RARC.⁴⁹

In one of our previous experiences, when we opened the ileum in RARC to form a Studer pouch intracorporeally, we saw the moving parasites on the mucosal surface. They were 5-mm sized and yellow-white colored. We removed all of them with the laparoscopic grasper and sent them for pathologic and parasitologic evaluation. Then we completed iRARC successfully. The pathologic and parasitologic evaluation results were reported as Taenia saginata. So, stool sample evaluation should be done in the preoperative period for the possible presence of intestinal parasitic diseases particularly in patients with bladder cancer coming from areas with an increased incidence of intestinal parasitic diseases before opening the bowel segments during surgery to perform radical cystectomy and urinary diversion.⁵⁰

Complications of lengthy surgery, pneumoperitoneum, lithotomy position, compartment syndrome

One of the disadvantages of robotic approach is the longer operation time that was reported by a very recent systematic review and meta-analysis.⁵¹ Longer operation time is expected to lead to longer exposure to pneumoperitoneum that might particularly have a negative impact on the lung function that is explained above. Yamada et al stated that lower extremity neuropathy is a well-recognized complication that arises during robotic surgeries in lithotomy-Trendelenburg position due to the persistent compression to the nerves, and robotic prostate cancer and bladder cancer surgeries are examples.⁵²

Lower limb compartment syndrome was reported to occur in RARP that has a low incidence. Long operation times, surgical inexperience, poor patient positioning, obesity, and vascular disease were suggested as risk factors for this condition.^53,54

Conclusion

iRARC is increasingly being performed with a remarkable progressing success. Except the special contraindications, the technique has been suggested to be safe, reproducible, and oncologically feasible. Increasing expertise of the surgeon and technological improvements are expected to provide better operative and functional outcomes.